Mein Warenkorb

IL-7

IL-7 Molekülinformation

Englischer NameInterleukin-7Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel5Target-AliasInterleukin 7,IL7
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Englischer NameInterleukin-7
Target-AliasInterleukin 7,IL7
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel5
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical

IL-7 Molekülhintergrund

Interleukin 7 is also known as IL7, IL-7, and is a hematopoietic growth factor secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells, but is not produced by lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells, It also stimulates proliferation of all cells in the lymphoid lineage (B cells, T cells and NK cells). It is important for proliferation during certain stages of B-cell maturation, T and NK cell survival, development and homeostasis. IL-7 is a cytokine important for B and T cell development. This cytokine and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. IL-7 binds to the IL-7 receptor, a heterodimer consisting of Interleukin-7 receptor alpha and common gamma chain receptor. Il-7 promotes hematological malignacies (acute lymphoblastic leukemia, T cell lymphoma). Elevated levels of IL-7 have also been detected in the plasma of HIV-infected patients. IL-7 as an immunotherapy agent has been examined in many pre-clinical animal studies and more recently in human clinical trials for various malignancies and during HIV infection. IL-7 could also be beneficial in improving immune recovery after allogenic stem cell transplant.

IL-7 Molekülalias

IL7,Interleukin-7

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine)Phase 1 ClinicalGuangdong Zhaotai Invivo Biomedicine Co Ltd, Hunan Zhaotai Yongren Biotech Co LtdCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung
Details
HCW-9206HCW-9206Phase 1 ClinicalHCW Biologics IncLeukemia, Myeloid, Acute; Solid tumours
Details
ADP-TILIL7ADP-TILIL7Phase 1 ClinicalAdaptimmune Therapeutics PlcMelanoma
Details
GSK-3888130-BGSK3888130B; GSK-3888130; GSK-3888130-BPhase 1 ClinicalGlaxosmithkline PlcColitis, Ulcerative; Multiple Sclerosis
Details
BNT-152BNT-152Phase 1 ClinicalBiontech SeSolid tumours
Details

Produktrezensionen

  • Molekülinformation
  • Produktliste
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns